Navin Fluorine International Ltd-$ — Q1 FY27 earnings call
Summary generated by AI from the official transcript Navin Fluorine International Ltd-$ filed with BSE on 11 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Navin Fluorine reported consolidated revenue of Rs 1,045 crore for Q1 FY27, up 44% year-on-year, with EBITDA of Rs 357 crore and PAT of Rs 243 crore. Management announced new capex of Rs 90 crore for advanced materials adoption capacity and Rs 125 crore for CDMO Phase 2 cGMP4 capacity, alongside a DRDO technology development partnership and progress on the Chemours liquid cooling project. All three business verticals - HPP, specialty chemicals and CDMO - posted year-on-year revenue growth during the quarter.
Numbers mentioned
Revenue: INR1,045 crores (Q1 FY27)
p. 5
“On a consolidated level, we reported a revenue of INR1,045 crores for the quarter, reflecting a strong year-on-year growth of 44%.”
Anish Ganatra, page 5 of the filed PDF · View the filing
Operating EBITDA: INR357 crores (Q1 FY27)
p. 5
“Operating EBITDA for Q1 FY '27 was INR357 crores with a growth of 73% compared to the same quarter last year.”
Anish Ganatra, page 5 of the filed PDF · View the filing
Operating EBITDA margin: 34.2% (Q1 FY27)
p. 5
“The operating EBITDA margin stood at a solid 34.2%, a growth of 566 basis points versus Q1 of last year.”
Anish Ganatra, page 5 of the filed PDF · View the filing
Operating PBT: INR283 crores (Q1 FY27)
p. 5
“Operating PBT for the quarter was INR283 crores, reporting an increase of 101%.”
Anish Ganatra, page 5 of the filed PDF · View the filing
Profit after tax: INR243 crores (Q1 FY27)
p. 6
“Profit after tax stood at INR243 crores, registering a growth of 108%.”
Anish Ganatra, page 6 of the filed PDF · View the filing
Operating cash flow: INR173 crores (Q1 FY27)
p. 6
“Operating cash flows for Q1 stood at INR173 crores, and Navin also became net debt free during the quarter.”
Anish Ganatra, page 6 of the filed PDF · View the filing
Net working capital days: 81 days of sales (Q1 FY27)
p. 6
“Our net working capital days stood at 81 days of sales, which is again within the financial frame.”
Anish Ganatra, page 6 of the filed PDF · View the filing
HPP revenue: INR540 crores (Q1 FY27)
p. 5
“the HPP business continued to deliver a strong performance during the quarter with revenue of INR540 crores, registering a 33% growth year-on-year, driven by healthy volume growth and improved realizations.”
Nitin Kulkarni, page 5 of the filed PDF · View the filing
Specialty chemicals revenue: INR325 crores (Q1 FY27)
p. 5
“Our specialty chemicals business has reported a revenue of INR325 crores, registering a growth of 48% year-on-year.”
Nitin Kulkarni, page 5 of the filed PDF · View the filing
CDMO revenue: INR180 crores (Q1 FY27)
p. 5
“Revenue for quarter 1 FY '27 stood at INR180 crores, growing 82% year-on-year with strong outlook for the year.”
Nitin Kulkarni, page 5 of the filed PDF · View the filing
Renewable energy investment: INR15.73 crores
p. 4
“A renewable energy project, an investment of INR15.73 crores in a group captive hybrid renewable project for 14.9 megawatts of renewable power supports our sustainability and decarbonization goals.”
Vishad Mafatlal, page 4 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Advanced materials capex — INR90 crores
stated firmly by Vishad Mafatlal
p. 4
“The Board has approved a new capex of INR90 crores funded through internal accruals towards setting up adoption capacities for our advanced materials business.”
Vishad Mafatlal, page 4 of the filed PDF · View the filing
CDMO Phase 2 cGMP4 capex — INR125 crores · Q4 FY27
stated firmly by Vishad Mafatlal
p. 4
“we have initiated in our CDMO business, Phase 2 cGMP4 capex of INR125 crores funded through internal accruals, expected to operationalize by Q4 FY '27.”
Vishad Mafatlal, page 4 of the filed PDF · View the filing
Chemours project completion — Q2 FY27
stated firmly by Vishad Mafatlal
p. 4
“Chemours project, which also form a part of this vertical is targeted for completion by end of Q2 FY '27.”
Vishad Mafatlal, page 4 of the filed PDF · View the filing
HFC capacity expansion commissioning — 15,000 metric tons of R32 · Q3 FY27
stated firmly by Vishad Mafatlal
p. 4
“the additional HFC capacity equivalent to up to 15,000 metric tons of R32 remains on track for commissioning in Q3 FY '27.”
Vishad Mafatlal, page 4 of the filed PDF · View the filing
MPP capacity debottlenecking completion — Q3 FY27
stated firmly by Vishad Mafatlal
p. 4
“debottlenecking activities at our Dahej MPP facilities are progressing well and are expected to be completed by Q3 FY '27.”
Vishad Mafatlal, page 4 of the filed PDF · View the filing
Renewable energy contribution — more than 60% of energy requirements
stated conditionally by Vishad Mafatlal
p. 4
“Once operational, this project is expected to meet more than 60% of our energy requirements through renewable sources.”
Vishad Mafatlal, page 4 of the filed PDF · View the filing
CDMO capex asset turn — 3x · FY29
stated as an aspiration by Anish Ganatra
p. 14
“Yes, the $100 million is very much on track. I mean there is -- I mean that's -- we are now talking of exploding that business, yes. So, FY '29, 3x is correct, and it will actually be longer than that, but I've given a near-term view of what that would be.”
Anish Ganatra, page 14 of the filed PDF · View the filing
CDMO business revenue — $100 million · this year
stated firmly by Anish Ganatra
p. 14
“Yes, the $100 million is very much on track.”
Anish Ganatra, page 14 of the filed PDF · View the filing
Contracted R32 capacity — 35% to 45% of total capacities · over five years
stated as an aspiration by Anish Ganatra
p. 8
“our idea is, as we've said before, to look at about 35% to 45% of the total capacities will be contracted for the five-year period.”
Anish Ganatra, page 8 of the filed PDF · View the filing
EBITDA margin range — 32%, 33%, plus/minus 1% · next one to two years
stated conditionally by Anish Ganatra
p. 15
“we've got enough to have confidence from a point of view of operating leverage that what we are talking about will be in the range of that 32%, 33%, plus/minus 1% here or there.”
Anish Ganatra, page 15 of the filed PDF · View the filing
HFO contract with Honeywell — beyond FY29
stated conditionally by Anish Ganatra
p. 16
“the original term was for seven years, and there is an auto extension to that at Honeywell's interest for further three years.”
Anish Ganatra, page 16 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said the vertical targets data centers, electronics, defense and semiconductors, and that HPP, specialty and CDMO all have tailwinds; growth beyond FY28 depends on newer capex including adoption capacities and electronic grade HF.
Answered by Anish Ganatra
Asked by Ankur: What end-use applications is the advanced materials capex targeting, and what is the growth outlook beyond FY29?
p. 6
“The idea here, Ankur, is that this vertical will focus on niche sort of applications in high-growth sectors, mainly data centers, electronics, defense and semiconductors”
Anish Ganatra, page 6 of the filed PDF · View the filing
Management said pricing is not fully controllable, but the company will remain the most competitive cost manufacturer with operating leverage supporting margins regardless of pricing environment.
Answered by Anish Ganatra
Asked by Madhav: How should investors read R32 pricing given the capacity expansion and peak revenue figures?
p. 8
“What we actually do is we tend to remain as the most competitive cost manufacturer of 32.”
Anish Ganatra, page 8 of the filed PDF · View the filing
Management attributed the margin change to campaign-driven variability and the commissioning of AHF capacity in the subsidiary, where intercompany transfer of HF at arm's length reduces the subsidiary's captured margin.
Answered by Anish Ganatra
Asked by Sanjesh Jain: Why did the subsidiary (NFASL) EBITDA margin drop sequentially versus standalone?
p. 10
“as AHF capacity commissions, the transfer of material from Dahej into Surat or NFIL is where the value is occurring, right?”
Anish Ganatra, page 10 of the filed PDF · View the filing
Management said three more molecules are expected to have FDA readouts within 8 to 12 months, part of a broader diversified pipeline.
Answered by Anish Ganatra
Asked by Sanjesh Jain: How many CDMO molecules are progressing toward FDA readouts?
p. 10
“we have got three more molecules that are expected to go to an FDA readout over the next 8 to 12 months.”
Anish Ganatra, page 10 of the filed PDF · View the filing
Management described a phased rollout where about five products already lab-approved will move to commercial scale first, while new products enter the pipeline.
Answered by Anish Ganatra
Asked by Rohit Nagraj: What is the qualification timeline for advanced materials products moving from pilot to commercial scale?
p. 10
“we have at least about four to five products that have already been qualified by the customer. And this adoption capacity will take it to commercial scale qualification”
Anish Ganatra, page 10 of the filed PDF · View the filing
Management confirmed Navin is the only supplier to Chemours for this product and said scale-up timing is being watched via a previously stated window.
Answered by Anish Ganatra
Asked by Rohit Nagraj: Is Navin the largest supplier for Chemours' 2-phase cooling liquid and will scalability accelerate once the project commissions?
p. 11
“So we are the only supplier to Chemours. We are today supplying the products that Chemours is actually supplying at the other end.”
Anish Ganatra, page 11 of the filed PDF · View the filing
Management agreed volume is the main driver but noted three of the five new molecules are patented and face less pricing pressure, and growth also comes from productivity and capacity extension.
Answered by Anish Ganatra
Asked by Jason: Is the specialty chemicals growth mainly volume-led given gradual agchem recovery?
p. 11
“out of those five, there are three which are patented molecules and do not face the kind of pricing pressure that one would expect.”
Anish Ganatra, page 11 of the filed PDF · View the filing
Management pointed to a 30-40 molecule pipeline with about 10 in late stage and FDA readouts expected as the signal to watch for broadening.
Answered by Anish Ganatra
Asked by Sajal Kapoor: What evidence should indicate the CDMO business is broadening beyond the primary European partner?
p. 13
“Today, if I talk about my molecule pipeline, we are talking about 30 to 40 molecules that I'm actively working on.”
Anish Ganatra, page 13 of the filed PDF · View the filing
Management explained that last year's high HF pricing inflated the prior year's margin base, and current raw material cost pressures from global tensions are affecting gross margins, offset partly by productivity gains.
Answered by Anish Ganatra
Asked by Vidrum Mehta: Why haven't margins expanded more given favorable segment mix shifts toward HPP and CDMO?
p. 15
“Today, as we are talking in a heightened global war tensions with supply chain risk, the cost of raw materials increasing, et cetera, that profile will change.”
Anish Ganatra, page 15 of the filed PDF · View the filing
Management said it will create two core platforms plus analytical equipment augmentation at the Surat site, distinct from a pilot plant since lab-scale approval is already complete.
Answered by Anish Ganatra
Asked by Siddharth: What will the Rs 90 crore advanced materials capex specifically build, and where?
p. 16
“this capacity will create sort of two core platforms and also augment our capabilities around equipment, etcetera, for analytical.”
Anish Ganatra, page 16 of the filed PDF · View the filing
Management said the contract has a long runway given the original seven-year term plus a possible three-year extension.
Answered by Anish Ganatra
Asked by Siddharth: How should investors think about the Honeywell HFO contract beyond FY27?
p. 16
“the original term was for seven years, and there is an auto extension to that at Honeywell's interest for further three years. So we have enough runway to go.”
Anish Ganatra, page 16 of the filed PDF · View the filing
Risks flagged
Pricing pressure in the agrochemicals specialty business, particularly in the well-supplied LatAm market
p. 7
“While volume growth is recovering, pricing pressure continues to remain, particularly in the LatAm market, which is already well supplied, right?”
Anish Ganatra, page 7 of the filed PDF · View the filing
R32 pricing is outside the company's control and subject to market dynamics
p. 8
“Now in the near term, one has to look at beyond pricing because pricing is neither in your hands nor my hands.”
Anish Ganatra, page 8 of the filed PDF · View the filing
India expected to be oversupplied in R32 for the next five years, requiring reliance on export markets
p. 8
“We all know that in the next five-years, all the Indian players will not -- India is going to be oversupplied for five years, right?”
Anish Ganatra, page 8 of the filed PDF · View the filing
Rising raw material costs amid global geopolitical tensions and supply chain risk
p. 15
“Today, as we are talking in a heightened global war tensions with supply chain risk, the cost of raw materials increasing, et cetera, that profile will change.”
Anish Ganatra, page 15 of the filed PDF · View the filing
Uncertainty over whether pipeline molecules will succeed at FDA approval stage
p. 13
“Now do we have anything to know crystal ball case and know for sure if all three are going to work out on an FDA approval? We don't.”
Anish Ganatra, page 13 of the filed PDF · View the filing
Scale-up risk for advanced materials products moving from lab to commercial scale
p. 16
“Of course, there is scale up involved and the risks associated with not being able to scale up.”
Anish Ganatra, page 16 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.